Patents by Inventor Daniel R. Getts

Daniel R. Getts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PARTICLES ENCAPSULATING FUSION PROTEINS CONTAINING LINKED EPITOPES
    Publication number: 20240122864
    Abstract: The present invention provides compositions comprising biodegradable particles that encapsulate two or more epitopes linked together by one or more linkers that are susceptible to cleavage by specific proteases. The present invention further provides methods for inducing antigen-specific tolerance and protective immune responses and for the treatment inflammatory diseases, such as autoimmune diseases, allergies, cancers, or infectious diseases.
    Type: Application
    Filed: June 12, 2023
    Publication date: April 18, 2024
    Inventor: Daniel R Getts
  • IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20240000830
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Application
    Filed: June 6, 2023
    Publication date: January 4, 2024
    Inventor: Daniel R. GETTS
  • Peptide conjugated particles
    Patent number: 11826407
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: November 28, 2023
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Process for the preparation of tolerizing immune-modulating particles
    Patent number: 11484506
    Abstract: The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: November 1, 2022
    Assignee: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.
    Inventors: Daniel R. Getts, Frank Fokta, Ryan Pearson
  • METHOD OF INDUCING ANTIGEN-SPECIFIC TOLERANCE IN A SUBJECT BY ADMINISTERING A COMPOSITION COMPRISING AN APOPTOTIC BODY SURROGATE AND COUPLED IMMUNODOMINANT ANTIGENIC EPITOPES ASSOCIATED WITH AUTOIMMUNE DISEASE
    Publication number: 20220273778
    Abstract: The present invention provides compositions and methods for inducing antigen-specific tolerance in a subject. In one embodiment, the present invention provides a composition comprising an apoptotic body and an epitope of an antigen. Also provided herein are methods of preparing and administering the composition. The composition and methods provided herein can induce antigen-specific tolerance in a subject.
    Type: Application
    Filed: November 22, 2021
    Publication date: September 1, 2022
    Inventors: Stephen D. Miller, Michael A. Pleiss, Daniel R. Getts, Aaron Martin
  • Peptide conjugated particles for the treatment of inflammation
    Patent number: 11413337
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 16, 2022
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick Mccarthy
  • Peptide conjugated particles
    Patent number: 11389517
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: July 19, 2022
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Compositions Comprising Apoptotic Signaling and Methods for Induction of Antigen-Specific Tolerance
    Publication number: 20220143160
    Abstract: The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to include antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Inventors: Stephen D. Miller, Russell L. Bromley, Michael A. Pleiss, Daniel R. Getts, Aaron Martin
  • PEPTIDE CONJUGATED PARTICLES
    Publication number: 20220008523
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: September 22, 2021
    Publication date: January 13, 2022
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Peptide Conjugated Particles
    Publication number: 20220000994
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Peptide conjugated particles
    Patent number: 11160851
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: November 2, 2021
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Peptide conjugated particles
    Patent number: 11129881
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: September 28, 2021
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • PROCESS FOR THE PREPARATION OF TOLERIZING IMMUNE-MODULATING PARTICLES
    Publication number: 20210290558
    Abstract: The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 23, 2021
    Inventors: Daniel R. Getts, Frank Fokta, Ryan Pearson
  • Modified immune-modulating particles
    Patent number: 11020424
    Abstract: The presently claimed invention relates to methods of reducing the duration or severity of an inflammatory immune response. In embodiments, the method comprises administering poly (lactic acid) (PLA) particles, poly (glycolic acid) (PGA) particles, poly (lactic-co-glycolic acid) (PLGA) particles, or combinations thereof; wherein said particles are modified to contain one or more carboxyl groups on the particle's surface. In embodiments, the particles do not comprise therapeutically active ingredients.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: June 1, 2021
    Assignee: onCour Pharma, Inc.
    Inventors: Daniel R. Getts, Rachael Terry, Nicholas King
  • TREATMENT OF CELIAC DISEASE WITH TOLERIZING PARTICLES
    Publication number: 20210030892
    Abstract: The present disclosure relates to methods for treating Celiac Disease using tolerizing immune modifying particles that encapsulate antigenic material from the gliadin protein or other related proteins.
    Type: Application
    Filed: February 8, 2019
    Publication date: February 4, 2021
    Inventor: Daniel R. GETTS
  • Peptide Conjugated Particles
    Publication number: 20210000932
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: April 17, 2020
    Publication date: January 7, 2021
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • MODIFIED IMMUNE-MODULATING PARTICLES
    Publication number: 20200338116
    Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated poly-styrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.
    Type: Application
    Filed: April 7, 2020
    Publication date: October 29, 2020
    Inventors: Daniel R. GETTS, Rachael TERRY, Nicholas KING
  • Peptide Conjugated Particles
    Publication number: 20200330569
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Peptide Conjugated Particles
    Publication number: 20200316181
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: April 13, 2020
    Publication date: October 8, 2020
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20200276228
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Application
    Filed: May 15, 2020
    Publication date: September 3, 2020
    Inventor: Daniel R. GETTS